CLU rs11136000 promotes early cognitive decline in Parkinson's disease

Mov Disord. 2020 Mar;35(3):508-513. doi: 10.1002/mds.27949. Epub 2020 Jan 13.

Abstract

Background: The C allele of the rs11136000 genetic variant of the clusterin gene has been associated with increased risk of Alzheimer's disease. However, a comprehensive characterization of the role of this genetic variant in early cognitive deterioration in PD is lacking.

Methods: Using the Parkinson's Progression Markers Initiative database, we compared baseline and 5-year cognitive performance between high-risk and low-risk clusterin genotypes.

Results: At baseline, recently diagnosed and drug-naive de novo PD patients with the high-risk clusterin genotype showed lower cognitive scores in memory and executive function tests. These differences were even higher at the 5-year follow-up, when they showed a higher prevalence of clinically diagnosed mild cognitive impairment or dementia. They also showed cortical thinning at baseline and increased annual thinning in frontal and posterior cortical regions.

Discussion: Our results provide evidence of this clusterin genotype promoting early cognitive deterioration in PD, but further research is needed to delineate the specific neurodegenerative pathways underlying this clinical association. © 2020 International Parkinson and Movement Disorder Society.

Keywords: CLU rs11136000; Parkinson's disease; cognitive impairment; cortical thinning.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Alzheimer Disease*
  • Clusterin / genetics
  • Cognitive Dysfunction* / genetics
  • Disease Progression
  • Genotype
  • Humans
  • Neuropsychological Tests
  • Parkinson Disease* / complications
  • Parkinson Disease* / genetics

Substances

  • CLU protein, human
  • Clusterin